Home > Focus Areas > DLBCL Connect > Post
4yr
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33202794/
The most common type of non-Hodgkin lymphoma in adults is diffuse large B-cell (DLBCL). There is a historical unmet need for more effective therapies in the 2nd and 3rd line setting. Emerging immunochemotherapies have shown activity in small studies of heavily pre-treated patients with prolonged rem ...
-
Mark Fesler4yrIt’s exciting how many supposedly non cross resistant targets we are identifying for this disease including cd19 and cd79 in addition to cd20. These therapies with various mechanisms of action hold promise in making dlbcl an illness even without intensive therapies that patients can live with for years ...